Addex director resets option, share strikes to $0.032
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Addex Therapeutics Ltd. (ADXN) director Isaac Manke reported repricing equity incentives on September 2, 2026. An option covering 50,000 common shares and deferred strike obligations on 219,561 previously acquired shares were reset to an exercise or strike price of $0.032 per share, with all other terms unchanged and no net change in the number of shares or options held. These actions are described as exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act and were not made under a Rule 10b5-1 trading plan.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock-option (Right to Buy) F3, F2 | 50,000 | $0.00 | $0.00 |
| Grant/Award | Stock-option (Right to Buy) F3, F2 | 50,000 | $0.00 | $0.00 |
| Disposition | Common Stock F1 | 219,561 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 219,561 | $0.00 | $0.00 |
Footnotes (3)
- F1. Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.
- F2. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.
- F3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.
Key Figures
Key Terms
deferred strike price payment plan financial
Rule 16b-6(d) regulatory
Rule 16b-3 regulatory
exercise price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Addex Therapeutics (ADXN) director Isaac Manke report on this Form 4?
What new strike or exercise price was set in the Addex Therapeutics (ADXN) Form 4?
What prior exercises and strike prices are referenced in the Addex Therapeutics (ADXN) Form 4 footnotes?
Was a Rule 10b5-1 trading plan involved in the Addex Therapeutics (ADXN) transactions?
What foreign exchange rate was used for the Addex Therapeutics (ADXN) strike price conversions?
AI-generated analysis. How Rhea-AI works. Not financial advice.